Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

The basal ganglia (BG) are a highly organized network, where different parts are activated
for specific functions and circumstances. The BG are involved in movement control, as well …

l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic treatment of
Parkinson's disease (PD). However, long-term administration of l-DOPA is marred by the …

The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's
disease (PD) for over 40 years. However, the response to this treatment changes with …

Dopamine is an essential neurotransmitter for many brain functions, and its dysfunction has
been implicated in both neurological and psychiatric disorders. Parkinson's disease is an …

The pathophysiology of levodopa-induced dyskinesias (LID) in Parkinson's disease is not
well understood. We have recorded local field potentials (LFP) from macroelectrodes …

Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease, but its utility is limited by a development of motor fluctuations and …

Objective: Striatal serotonin projections have been implicated in levodopa‐induced
dyskinesia by providing an unregulated source of dopamine release. We set out to …

This unit provides detailed protocols for establishing rodent models of l‐DOPA‐induced
dyskinesia. The 6‐hydroxydopamine (6‐OHDA) lesion procedure is described in more detail …

J. Neurochem.(2010) 112, 1465–1476. Abstract l‐DOPA‐induced dyskinesia in Parkinson's
disease is associated with large increases in brain dopamine (DA) levels following drug …